Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Paradigm Biopharmaceuticals ( (AU:PAR) ) has provided an update.
Paradigm Biopharmaceuticals has announced a proposed securities purchase plan, under which it aims to issue up to 10,526,316 new fully paid ordinary shares to eligible investors. The offer is structured with a record date of 24 April 2026, a closing date of 26 May 2026 and an issue date of 2 June 2026, signalling a targeted equity raising to fund ongoing operations and growth plans.
In addition to the new shares, the company plans to issue an equal number of quoted options expiring on 1 December 2026, or 20 business days after a specified announcement, with an exercise price of $0.2375, and another tranche of quoted options expiring 30 April 2029 with an exercise price of $0.38. The structure of the plan, combining shares with medium- and longer-dated options, is designed to provide Paradigm with immediate capital while offering participating shareholders leveraged exposure to potential future value creation.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Limited is an Australia-listed biopharmaceutical company focused on developing and commercialising therapeutic products. The company operates in the life sciences sector and accesses capital markets via the ASX to support its pipeline and corporate activities.
YTD Price Performance: -33.82%
Average Trading Volume: 1,214,546
Technical Sentiment Signal: Sell
Current Market Cap: A$101.6M
Find detailed analytics on PAR stock on TipRanks’ Stock Analysis page.